In the quiet machinery of the cell, a misfiring process called RNA splicing has long driven a rare blood cancer called myelodysplastic syndrome without yielding to treatment. Researchers at Mount Sinai and UC San Diego have now traced that molecular error to an altered protein — and discovered that drugs already approved for other cancers may be capable of exploiting it. The finding reminds us that medicine sometimes advances not by inventing new weapons, but by learning, at last, where to aim the ones already in hand.
Researchers identify MEK inhibitors as potential treatment for myelodysplastic syndrome
Solutions may already exist, waiting to be matched with the right target.
Mark
So they found that these RNA splicing mutations cause a specific protein to be overproduced. How did they know that MEK inhibitors would work against it?
Mimi
They tested it. They took cells with the mutations—both engineered ones and actual patient cells—and exposed them to MEK inhibitors. The cells responded. It wasn't a guess; it was observation.
Luke
But that's in a lab dish. We don't know yet if it works in patients. That's why they're running the clinical trial.
Mark
Right. So the MEK inhibitors are already FDA-approved for other cancers. That's a big advantage, isn't it?
Mimi
Exactly. The drugs exist. The safety profile is known. They don't have to start from scratch developing something new. They just have to test whether it works for this particular disease.
Luke
Though we should note—the mutations they studied are found in some MDS patients, not all. So this won't be a treatment for everyone with the disease.
Mark
How rare is MDS to begin with?
Mimi
It's described as a rare blood cancer. The source doesn't give a specific number of patients, but it's uncommon enough that finding effective treatments has been difficult.
Luke
And the source says these mutations also appear in other cancers. That could mean the findings have broader applications, but again, that's future work. Right now it's about testing in MDS.
Mark
When does the trial start?
Mimi
The source doesn't specify a timeline. It just says they're creating a clinical trial.
Luke
That's an important gap. We know it's planned, but not when patients might actually access it.
El Pulso
- MDS has long resisted effective treatment, leaving patients with a serious blood cancer and few meaningful options.
- The discovery that RNA splicing mutations produce an altered GNAS protein finally cracks open the disease's opaque biology.
- Lab models built from engineered stem cells confirmed the vulnerability — and real MDS patient cells responded to MEK inhibitors the same way.
- Because the same splicing mutations appear in other blood cancers and solid tumors, the implications reach well beyond MDS alone.
- A clinical trial is now launching to move MEK inhibitor treatment from laboratory proof to human patients — the critical next threshold.
In the quiet machinery of the cell, a misfiring process called RNA splicing has long driven a rare blood cancer called myelodysplastic syndrome without yielding to treatment. Researchers at Mount Sinai and UC San Diego have now traced that molecular error to an altered protein — and discovered that drugs already approved for other cancers may be capable of exploiting it. The finding reminds us that medicine sometimes advances not by inventing new weapons, but by learning, at last, where to aim the ones already in hand.
A research team at Mount Sinai and UC San Diego has identified how a rare blood cancer called myelodysplastic syndrome develops at the molecular level — and found that a class of already-approved drugs may be capable of stopping it. The work, published in Cancer Discovery in October 2021, centers on mutations that disrupt RNA splicing, a fundamental cellular process. Those mutations cause cells to overproduce an altered version of a protein encoded by the GNAS gene, and that excess, it turns out, creates a vulnerability that existing cancer drugs can exploit.
MDS has long frustrated oncologists. Its biology remained poorly understood, and no truly effective treatments existed. To change that, the team — led by Eirini Papapetrou and Gene Yeo — engineered stem cells to carry MDS-associated mutations, then guided them into the blood cell type most relevant to the disease. Advanced RNA analysis revealed a consistent pattern: the faulty splicing machinery elevates the altered GNAS protein, which in turn activates pathways that make cancer cells sensitive to MEK inhibitors. When both engineered cells and actual patient cells were exposed to these drugs, both responded.
The implications stretch further than MDS. The same RNA splicing mutations appear in other hematologic malignancies and solid tumors, suggesting the findings could eventually inform treatment across a broader range of cancers. Papapetrou noted this is the first demonstration that the altered GNAS protein is elevated in MDS cells carrying these mutations, and the first evidence that MEK inhibitors represent a viable therapeutic approach — while also pointing toward future efforts to target GNAS directly.
The team is now advancing to a clinical trial, translating a laboratory mechanism into a real possibility for patients who have had little to hope for. For the wider research community, the work offers a quieter lesson: that understanding the molecular roots of disease can reveal that the tools to treat it may already exist, simply waiting to be matched with the right target.
A team of researchers at Mount Sinai and UC San Diego has traced the molecular path by which a rare blood cancer develops—and in doing so, identified a class of drugs already sitting in the FDA's approved arsenal that might stop it. The work, published in Cancer Discovery in October 2021, centers on myelodysplastic syndrome, or MDS, a disease that has long resisted effective treatment and carries a grim prognosis. What the scientists discovered is that certain mutations disrupt a fundamental cellular process called RNA splicing, causing cells to produce an altered version of a protein encoded by the GNAS gene. That altered protein, it turns out, creates a vulnerability that existing cancer drugs can exploit.
Myelodysplastic syndrome is uncommon but serious—a malignancy of the blood with no truly effective treatments available to patients. The condition has haunted oncologists precisely because its biology remained opaque. The Mount Sinai and UC San Diego team, led by Eirini Papapetrou and Gene Yeo, set out to understand how the RNA splicing mutations actually drive the disease. They built laboratory models using stem cells, engineering them to carry the mutations found in MDS patients, then coaxed those cells into becoming hematopoietic progenitor cells—the cell type most relevant to blood cancers. Using advanced RNA analysis techniques, they traced what happens when these mutations are present.
What emerged from their work was a clear picture: the mutated RNA splicing machinery causes cells to produce more of the altered GNAS protein, and this excess activates cellular pathways that make the cancer cells vulnerable to a specific class of drugs called MEK inhibitors. These are not new compounds. MEK inhibitors have already been approved by the FDA for treating other cancers. The researchers tested this hypothesis by exposing both their engineered MDS cells and actual cells taken from MDS patients carrying these mutations to MEK inhibitor treatment. Both responded.
The significance extends beyond MDS alone. The same RNA splicing mutations appear in other blood cancers and in solid tumors as well, suggesting that the findings could eventually apply to a broader range of malignancies. Papapetrou noted in the study that this is the first time anyone has shown that the altered GNAS protein is elevated in cells with these mutations in the context of MDS, and the first demonstration that MEK inhibitors could be a viable treatment approach. She also pointed out that the work opens a door to future drug development specifically targeting GNAS itself.
The team is now moving forward with a clinical trial to test MEK inhibitors in actual MDS patients. This represents a shift from laboratory discovery to human testing—the moment when a promising mechanism in cells becomes a real therapeutic possibility. For patients with a disease that has offered few options, the trial represents a concrete next step. For the broader cancer research community, the work demonstrates how understanding the molecular machinery of disease can reveal that solutions may already exist, waiting to be matched with the right target.
Citas Notables
This work integrates isogenic models of disease with cutting-edge RNA-omics to converge onto a new target for MDS.— Gene Yeo, UC San Diego School of Medicine
Quieres la nota completa?
Lee el original en News-Medical.net ↗
Health & Medicine